New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
13:39 EDTAGN, VRX, CSPershing Square enlists Credit Suisse to help in Allergan effort, WSJ says
William Ackman's Pershing Square has hired Credit Suisse (CS), which is a firm known to have expertise in defending corporate clients against activist investors, for advice on the effort to have Valeant Pharmaceuticals (VRX) take over Allergan (AGN), says the Wall Street Journal. Reference Link
News For AGN;VRX;CS From The Last 14 Days
Check below for free stories on AGN;VRX;CS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 16, 2014
17:42 EDTAGN, VRXPershing Square's Ackman says Allergan's attack on Valeant unprecedented
Subscribe for More Information
10:36 EDTVRX, AGNTreasury calls on Congress to halt inversion deals
Subscribe for More Information
10:31 EDTAGNPershing Square Capital Management holds analyst/industry conference call
Subscribe for More Information
09:16 EDTAGN, VRXPershing Square sends letter to Allergan's board of directors
Pershing Square Capital Management announced it has sent a letter to Allergan's Board of Directors. Pershing Square last Friday filed definitive solicitation materials with the U.S. SEC to seek shareholder support for a special meeting of Allergan shareholders and is now actively soliciting shareholder support to call the meeting. At this special meeting, Allergan shareholders will be able to voice their opinions on a number of critical matters, including the proposed removal of six incumbent members of the Allergan board, the proposed appointment of an independent slate of directors and certain other proposed provisions to improve Allergan’s corporate governance.
08:16 EDTVRX, AGNLew's letter could bring 'chilly' tax inversion environment, says BMO Capital
Subscribe for More Information
07:59 EDTAGN, VRXTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
06:59 EDTCSCredit Suisse granted $3.7B RMBS bond bid list, Reuters says
Subscribe for More Information
July 15, 2014
11:13 EDTAGNPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
July 14, 2014
12:47 EDTAGN, VRXAllergan slides question Valeant growth, disclosures, says BMO Capital
Subscribe for More Information
08:13 EDTVRX, AGNAllergan reiterates belief that Valeant model unsustainable in new presentation
Subscribe for More Information
08:02 EDTVRX, AGNValeant submits HSR filing for proposed acquisition of Allergan
Subscribe for More Information
July 11, 2014
16:48 EDTVRX, AGNAllergan comments on Pershing Square’s definitive proxy solicitation
Allergan (AGN) provided the following comment in response to the definitive proxy solicitation filed by Pershing Square Capital Management in connection with Pershing Square’s request to call a Special Meeting of Stockholders. At the Special Meeting, if called, Allergan stockholders would be asked to remove a majority of the company’s existing directors in connection with Valeant Pharmaceuticals' (VRX) unsolicited exchange offer to acquire all outstanding common shares of Allergan for 0.83 shares of Valeant common stock and $72.00 in cash, or subject to proration, an amount of cash or a number of Valeant common shares with the implied value set forth in the exchange offer. Under the current Board’s leadership, which includes individuals with significantly more industry experience than Pershing Square’s recommended nominees, Allergan continues to execute on its plan to drive near- and long-term organic growth, enhance its growth prospects and continue generating significant value for all of Allergan’s stockholders. We believe Pershing Square’s attempt to replace a majority of the Allergan Board is a further effort to support Valeant in its bid to acquire Allergan at a grossly inadequate price that substantially undervalues the company and creates significant risks and uncertainties for Allergan stockholders. Valeant has repeatedly failed to address the serious concerns raised by Allergan and important members of the investment community about Valeant’s anemic organic growth driven by unsustainable price increases, among other fundamental business model issues. Allergan has a track record of consistently acting in the best interests of its stockholders and the Board remains confident in the company’s ability to create significantly more value than Valeant’s proposal.
11:54 EDTAGNAbbVie, Shire in active takeover talks, Bloomberg reports
AbbVie (ABBV) and Shire (SHPG) are in active talks about a potential merger after AbbVie raised its takeover offer for a fourth time, Bloomberg reports, citing people with knowledge of the matter. The talks are in the early stage and may not lead to an agreement, sources told Bloomberg. Shares of Shire are up 5%, or $12.04, to $250.65 following the report.
July 10, 2014
09:31 EDTVRXNestle acquires rights to aesthetic dermatology products in the U.S. and Canada
Subscribe for More Information
09:31 EDTVRXValeant completes filler, toxin asset sale to Galderma
Subscribe for More Information
07:08 EDTCSECB keeps tight grip on banks with health check results, Reuters says
The European Central Bank is targeting to keep a tight grip banks in the final phase of a balance sheet health check in October, giving them only 48 hours to review the test results before publishing them, according to Reuters, citing two people familiar with the matter. The assessment will look into banks’ balance sheets and measure their ability to handle shock and stress. Publicly traded European banks include Banco Santander (SAN), Barclays (BCS), Credit Suisse (CS), Deutsche Bank (DB), HSBC (HSBC), ING Groep (ING), Lloyds Banking (LYG), Royal Bank of Scotland (RBS) and UBS (UBS).
06:45 EDTCSCredit Suisse asks sentencing for aiding tax evasion be delayed, WSJ reports
Subscribe for More Information
July 9, 2014
18:31 EDTVRX, AGNShareholders urge Allergan to make large acquisition, FT reports
Subscribe for More Information
18:21 EDTVRX, AGNAllergan CEO seeks sizeable acquisitions, WSJ reports
Subscribe for More Information
06:19 EDTAGN, VRXAllergan plans broad restructuring plan, Bloomberg says
Allergan (AGN), the pharmaceutical maker that is being chased by Valeant (VRX) and Bill Ackman’s hedge fund, will shelve unpromising pipeline medicines and revamp management incentives, according to Bloomberg, citing two people with knowledge of the matter. The sources said that the restructuring plan, which is set to be explained during Allergan's upcoming earnings announcement, will also detail companywide cost reductions including some legacy expenses. Reference Link
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use